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Background: Venous thromboembolic events, either deep venous thrombosis or pulmonary embolism, are important com-
plications in patients undergoing kneeor hip arthroplasty. The purpose of this studywas to evaluate the effectiveness of amobile
compression device (ActiveCare1S.F.T.) with or without aspirin comparedwith current pharmacological protocols for prophylaxis
against venous thromboembolism in patients undergoing elective primary unilateral arthroplasty of a lower-extremity joint.
Methods: Amulticenter registry was established to capture the rate of symptomatic venous thromboembolic events following
primary knee arthroplasty (1551 patients) or hip arthroplasty (1509 patients) from ten sites. All patients were eighteen years of
age or older with no known history of venous thromboembolism, coagulation disorder, or solid tumor. Use of the compression
device began perioperatively and continued for a minimum of ten days. Patients with symptoms of deep venous thrombosis or
pulmonary embolism underwent duplex ultrasonography and/or spiral computed tomography. All patients were evaluated at
three months postoperatively to document any evidence of deep venous thrombosis or pulmonary embolism.
Results: Of 3060 patients, twenty-eight (0.92%) had venous thromboembolism (twenty distal deep venous thrombi,
three proximal deep venous thrombi, and five pulmonary emboli). One death occurred, with no autopsy performed.
Symptomatic venous thromboembolic rates observed in patients who had an arthroplasty of a lower-extremity joint using
the mobile compression device were noninferior (not worse than), at a margin of 1.0%, to the rates reported for phar-
macological prophylaxis, including warfarin, enoxaparin, rivaroxaban, and dabigatran, except in the knee arthroplasty
group, in which the mobile compression device fell short of the rate reported for rivaroxaban by 0.06%.
Conclusions: Use of the mobile compression device with or without aspirin for patients undergoing arthroplasty of a
lower-extremity joint provides a noninferior risk for the development of venous thromboembolism compared with current
pharmacological protocols.
Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
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D
eep venous thrombosis and pulmonary embolism
continue to be important complications after or-
thopaedic surgical procedures on the lower extrem-
ity. Several different modalities have been implicated as
responsible for the decreased prevalence of thromboembolic
events after surgery, including decreased surgical time and
early mobilization. Two broad groups of prophylactic modal-
ities are routinely used: pharmacological agents (anticoagulant
and antiplatelet) and mechanical compression devices. Both
are effective for the prevention of venous thromboembolism1-5;
however, each carries its own advantages and disadvantages.
The pharmacological agents have the risk of bleeding com-
plications1,3, which are especially high during the most vul-
nerable period for venous thromboembolism formation.
The mechanical methods have the potential risk of being less
efficacious, possibly related to variability in patient compli-
ance, and often are not used following discharge to home.
Many studies utilizing compression devices have been pub-
lished2,4,5, but all have relied on the use of compression de-
vices while the patient is hospitalized or in a rehabilitation
facility. The present study evaluated the efficacy of a mobile
compression device (ActiveCare1S.F.T; Medical Compression
Systems, Or Akiva, Israel) that is small and portable enough to
send the patient home with the device. The use of this com-
pression device for prophylaxis against venous thromboembolism
could be recommended if adequate efficacy could be established
and if it afforded a reduction in the risk of bleeding complications
associated with pharmacological agents.
Previously, a randomized prospective study was powered
to evaluate major bleeding events after hip arthroplasties with
the pharmacological agent most utilized worldwide (Lovenox;
enoxaparin) compared with the mobile compression device6.
The device was found to be associated with significantly less
major bleeding (p = 0.0004). Although the venous thrombo-
embolism rate was equal in each arm of this randomized study,
the study was not powered sufficiently to determine efficacy6.
We are aware of no large-scale studies or registries that have
evaluated the use of any mobile compression device with or
without aspirin to prevent venous thromboembolism after lower-
extremity joint arthroplasty.
In order to evaluate the efficacy of this mobile com-
pression device, a registry was established at ten high-volume
joint arthroplasty sites across the United States. The trial was
designed as a noninferiority trial, which aimed to demonstrate
that the mobile compression device was not worse than the
comparator pharmacological agents by more than a small,
prespecified amount (1.0%). The purpose of the registry was to
evaluate the effectiveness of the mobile compression device
with or without aspirin in lowering the potential risk of venous
thromboembolism during and after hip or knee arthroplasty
with the clinical end point of symptomatic deep venous throm-
bosis and/or pulmonary embolism within three months postop-
eratively. We compared these rates with the most commonly used
pharmacological agents and protocols for noninferiority in pre-
venting venous thromboembolism after arthroplasty of a lower-
extremity joint.
Materials and Methods
Orthopaedic surgeons at ten sites in the United States participated in a registryto collect data on postoperative venous thromboembolism in patients who
had an arthroplasty of a lower-extremity joint using the mobile compression
device. Data were collected from April 1, 2011, to September 30, 2011, on con-
secutive patients. Data collection was at one designated site that maintained and
analyzed the entire registry. Deidentified data from each of the other nine sites
were sent to the data collection site. Institutional review board approval
was obtained at each site. The trial was registered at ClinicalTrials.gov
(NCT01984190). One patient returned for a follow-up evaluation at four
weeks postoperatively and had no signs or symptoms of venous throm-
boembolism, but did not return at the three-month time point and was
considered lost to follow-up. Another patient died in the hospital on
postoperative day 3. The patient’s family declined an autopsy, and therefore
venous thromboembolic status could not be determined.
Inclusion and exclusion criteria were the same as those used in a prior
study on safety
6
and in other randomized controlled studies of prophylaxis
against venous thromboembolism
7-13
. Patients included in the registry were
eighteen years of age or older and underwent primary unilateral hip arthro-
plasty (including hip resurfacing) or primary unilateral knee arthroplasty
(including unicondylar knee arthroplasty) using only the mobile compression
device with or without aspirin for the prevention of venous thromboembolism.
Patients were excluded if they were scheduled for a revision surgery or had a
history of venous thromboembolism, a coagulation disorder, a solid malignant
tumor, or amajor surgical procedure in the threemonths prior to the arthroplasty.
The mobile compression device was applied to all patients perioperatively. The
devices were applied to the contralateral leg during the surgical procedures for
both knee and hip arthroplasties, and the device was applied to the operatively
treated leg at the completion of the procedure before transferring the patient to the
postanesthesia care unit. The device was used for a minimum of ten days with or
without aspirin. The decision to use aspirin and the aspirin dosage were at the
discretion of each surgeon participating in the registry.
This registry collected data on the occurrence of postoperative
venous thromboembolism in patients who had an arthroplasty of a lower-
extremity joint using this device for prophylaxis against venous thromboembo-
lism. In addition to portability, this device has a liquid crystal display to allow the
patient and medical personnel to monitor compliance. Another potential benefit
of this mobile compression device is the synchronized flow technology. This
technology synchronizes external compressions of the device to the patient’s ve-
nous phasic flow such that compression occurs in synchronizationwith the natural
venous phasic flow, allowing for a 66% increase in the peak venous velocity as
measured at the common femoral vein
14
.
If patients presented with symptoms consistent with a deep venous
thrombosis or pulmonary embolism at any time before three months post-
operatively, they were appropriately studied. At three months, patients completed
a questionnaire or were asked routine questions describing any diagnosed deep
venous thrombosis or pulmonary embolism event and were examined by
the site clinician for swelling, redness, tenderness, and excessive warmth of the
extremities. Symptomatic patients were studied by duplex ultrasound for deep
venous thrombosis and spiral computed tomography (CT)-angiography for pul-
monary embolism at the time of their symptoms within the three-month in-
terval. Deep venous thrombosis was defined as proximal if the thrombus
occurred in the popliteal vein or more proximally in the leg. Additional data
collected included type of surgery (hip or knee arthroplasty), patient de-
mographics (age, sex, height, and weight), and aspirin use (yes or no).
Aspirin usage was assessed dichotomously because the sites that used aspirin
had varying protocols for dose and duration of use. The frequency of an-
esthesia type (percent regional, general, or combined) was collected from
each of the sites. Patient characteristics are presented in the Appendix.
Statistical Analysis
The prevalence of venous thromboembolism with so-called standard phar-
macological prophylaxis is quite low; hence, establishing that the compression
device would be superior to these other regimens would be difficult. Taking
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this into consideration, we hypothesized that the mobile compression device
would have approximately the same efficacy as pharmacological prophylaxis
without the risk of major bleeding. We thus designed a noninferiority study of
the mobile compression device versus the standard pharmacological pro-
phylaxis, including warfarin, enoxaparin, rivaroxaban, and dabigatran, with
symptomatic end points and similar patient demographics.
Formally, a noninferiority study aims to demonstrate that a treatment
is not worse than the comparator (the control) by more than a prespecified,
small amount, commonly known as the noninferiority margin. The choice
of the noninferiority margin is somewhat subjective; we adopted a 1.0%
margin in the present study, with the belief that a 1.0% difference in venous
thromboembolism rates between the mobile compression device registry
cohort and the pharmacological comparators would not constitute a clinically
meaningful difference (e.g., a difference of such magnitude that a physician
might choose one or the other regimen). Our margin of 1.0% is more rig-
orous than the 1.5% margin used in most drug studies. The U.S. Food and
Drug Administration published guidelines for the design and conduct of
noninferiority trials
15
, and these trials have been widely adopted by the
pharmaceutical industry.
The noninferiority margin was based on absolute event rate differences.
We accepted that the mobile compression device was noninferior if the upper
bound of the one-sided 97.5% confidence interval (97.5% CI) around the
estimated difference in event rates was below the noninferiority margin. The
sample size calculation was based on symptomatic venous thromboembolism









from previously published clinical trial data. We calculated a
number of power comparisons prior to initiating the study. We found that
sample sizes of 1500 in the device group and any drug group would be sufficient
to achieve power in excess of 90% to detect a noninferiority margin difference
between the venous thromboembolism proportions in the two groups of 1.0%.
In these calculations, we considered venous thromboembolism rates in the drug
groups to be between 0.5% and 1.0% and the venous thromboembolism rate in
the device group was taken to be the drug group rate 1 1.0% under the null
hypothesis of inferiority. Power was calculated for the case when the actual
venous thromboembolism rate for the device was identical to that for the drug
comparator. The test statistic used was the one-sided score test, with the sig-
nificance level set at 0.025.
SPSS software (version 13.0; SPSS, Chicago, Illinois) and NCSS soft-
ware (version 7.1.21; NCSS, Kaysville, Utah) were used for sample size cal-
culations and analysis of the registry data. Means were calculated to describe
continuous variables (age, height, and weight), and frequencies were calcu-
lated to describe categorical variables (surgery type, aspirin use, and the
occurrence of symptomatic venous thromboembolism). Upper bound 97.5%
CIs were calculated around the observed difference in the rate of venous
thromboembolism between the mobile compression device and each drug
comparator.
Source of Funding
The funding for this registry was provided by Medical Compression Systems
(Or Akiva, Israel). Beyond funding the registry, Medical Compression Systems
did not participate in, nor did any of the authors receive compensation for, the
registry conduct, analysis, or manuscript preparation.
Results
Overall, symptomatic venous thromboembolism occurredin 0.92% (twenty-eight) of 3060 patients who had an
arthroplasty of a lower-extremity joint. Twenty-three patients
who had a joint arthroplasty (0.75%) experienced deep venous
thrombosis (three proximal and twenty distal thrombi), and
five patients (0.2%) had a pulmonary embolism (Table I). The








Venous thromboembolism (no. [%]) 28 (0.92) 8 (0.53) 20 (1.29)
Deep venous thrombosis (no. [%]) 23 (0.75) 5 (0.33) 18 (1.16)
Proximal deep venous thrombosis (no. [%]) 3 (0.10) 1 (0.07) 2 (0.13)
Pulmonary embolism (no. [%]) 5 (0.16) 3 (0.20) 2 (0.13)
TABLE II Rates of Symptomatic Venous Thromboembolism and Pulmonary Embolism in the Present Registry Study and in Previous Studies
with Similar Demographics















in the present study
28/3060 (0.92) 5/3060 (0.16) 8/1509 (0.53) 3/1509 (0.20) 20/1551 (1.29) 2/1551 (0.13)
Warfarin
7-10
45/2012 (2.24) 9/1816 (0.50) 15/534 (2.81) 0/338 (0.0) 30/1478 (2.03) 9/1478 (0.60)
Enoxaparin
11-14
68/6138 (1.11) 14/3932 (0.35) 26/3413 (0.76) 2/1207 (0.17) 42/2725 (1.54) 12/2725 (0.44)
Rivaroxaban
11-14
39/6132 (0.64) 1/6132 (0.02) 12/3405 (0.35) 1/3405 (0.03) 27/2727 (0.99) 0/2707 (0.0)
Dabigatran
15-17
69/5918 (1.17) 10/5918 (0.17) 28/3294 (0.85) 7/3294 (0.21%) 41/2624 (1.56) 3/2624 (0.11)
*The values are given as the number of patients affected divided by the total number in the study, with the percentage in parentheses. Symptomatic deep venous
thrombosis location (proximal versus distal) was not specified in published results for the pharmacological agents. The 97.5% confidence intervals are presented in Figures
1-A, 1-B, and 1-C.
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1509 patients managed with a hip arthroplasty had eight ve-
nous thromboembolic events (a rate of 0.5%), with five deep
venous thrombi (one proximal and four distal thrombi) and
three pulmonary emboli. The rate of venous thromboembo-
lism in the 1551 patients who had a knee arthroplasty was 1.3%
(twenty patients), with eighteen deep venous thrombi (two
proximal and sixteen distal thrombi) and two pulmonary
emboli (Table I). No fatal pulmonary emboli were reported.
One death of a patient with a long-standing history of cardiac
disease and previous cardiac stent placement was reported.
‘‘Coronary failure’’ was listed as the cause of death, and the
family was unwilling to allow an autopsy, so pulmonary em-
bolism could not be ruled out. The association between aspirin
use and the occurrence of venous thromboembolism could not
be assessed; among the twenty-eight patients who experienced
venous thromboembolism, thirteen (46.4%) were using aspirin
and fifteen (53.6%) were not.
The rate of symptomatic venous thromboembolism was
reported as 2.2% for warfarin16-19, as 1.1% for enoxaparin8,11-13, as
0.64% for rivaroxaban8,11-13, and as 1.2% for dabigatran9,10,20 after
arthroplasty of a lower-extremity joint (Table II). The rates of
symptomatic venous thromboembolism observed in patients
who had an arthroplasty of a lower-extremity joint using the
mobile compression device were noninferior at a margin of
1.0% to the rates reported for pharmacological prophylaxis,
including warfarin, enoxaparin, rivaroxaban, and dabigatran
(Figs. 1-A, 1-B, and 1-C). In the knee arthroplasty group, the
mobile compression device fell short of the noninferior 1.0%
margin to rivaroxaban by 0.06%, but it was noninferior at the
1.0% margin for all other knee and hip arthroplasty groups.
Fig. 1-A
Fig. 1-B
Fig. 1-A Observed rate differences for venous thromboembolism (venous thromboembolism rate with the mobile compression device minus the venous
thromboembolism rate with the pharmacological comparator, which is represented by the circular markers) and the 97.5% confidence intervals between
the mobile compression device and the current pharmacological comparators in patients who had an arthroplasty of a lower-extremity joint. Fig. 1-B
Observed rate differences for venous thromboembolism (venous thromboembolism rate with the mobile compression device minus venous thrombo-
embolism rate with the pharmacological comparator, which is represented by the circularmarkers) and the 97.5% confidence intervals between themobile
compression device and the current pharmacological comparators in patients who had a hip arthroplasty.
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Discussion
We evaluated whether the rates of symptomatic venousthromboembolism associated with the mobile compres-
sion device with or without aspirin were noninferior compared
with those for warfarin16-19, enoxaparin8,11-13, rivaroxaban8,11-13,
and dabigatran9,10,20 in patients who had hip arthroplasty, patients
who had knee arthroplasty, and combined groups of patients
who had a hip or knee arthroplasty. These reports compared
favorably with the finding in our study of a rate of 0.92% for
symptomatic venous thromboembolism after arthroplasty of a
lower-extremity joint. Anticoagulants, however, carry an in-
creased risk of major and minor bleeding events. This has been
well-documented for enoxaparin21,22, as well as in a previous
study comparing this specific device with enoxaparin6. The
bleeding risk profiles of warfarin and dabigatran are generally
similar to enoxaparin, which is most commonly utilized as the
control group in the clinical trials for these newer anticoagu-
lants23,24. Rivaroxaban, on the other hand, has a higher risk of
bleeding compared with enoxaparin, but is more efficacious at
preventing symptomatic venous thromboembolism23. This is
important information for the orthopaedic surgeon providing
an alternative to pharmacological methodology without the risk
of major bleeding and with similar efficacy. A cost analysis for
the prevention of major bleeding events has been previously
published25. Because of variations in cost by region and by
facility, no comparison with other compression devices could
reasonably be conducted. Although we know of no studies on
the prevention of venous thromboembolism with the use of
inpatient compression systems as monotherapy with symptom-
atic end points during hospitalization and follow-up after
discharge, Froimson et al. compared this mobile compression
device with the standard nonmobile compression device com-
monly used in acute care settings following lower-extremity
arthroplasty26. The mobile compression device showed a 70%
reduction in venous thromboembolic events compared with the
nonmobile compression device (when both arms were used as
adjunctive therapy to enoxaparin).
A series of guidelines have been developed and published
by the American College of Chest Physicians (ACCP)27 and by
the American Academy of Orthopaedic Surgeons (AAOS)28.
These guidelines utilized a systematic review of the current
literature to determine an ideal or best methodology and du-
ration for prophylaxis against venous thromboembolism. Both
guidelines use symptomatic end points with duplex ultrasound
documentation for deep venous thrombosis and imaging studies
for confirmation of pulmonary embolism.
The limitations of our study are those of any registry that
lacks a randomized control group. Selection bias is a concernwith
patient registries. We designed the mobile compression device
registry to utilize the same inclusion and exclusion criteria that
were used in randomized clinical trials assessing the efficacy of
pharmacological agents for prophylaxis against venous throm-
boembolism. The patients enrolled consecutively in this registry
had similar demographics to those reported in the clinical trials of
the pharmacological agents. A surgeon at one or more sites could
have possibly deviated from the inclusion and exclusion criteria
when deciding which of his or her patients should receive the
device, potentially resulting in a higher or lower-risk cohort of
patients enrolled at that site. The rate of venous thromboembo-
lism at each of the ten sites was similar, leading to the conclusion
that the registry protocol was followed cohesively. A selection bias
could have also resulted if not all patients who received the device
were included in the registry. However, we had only one patient
lost to follow-up, who had no signs or symptoms of venous
thromboembolism at one month postoperatively.
The registry had a limited data set, and neither bleeding
rates nor compliance were documented. These limitations were
offset by a previous study of the device6, which showed a 0% rate
of major bleeding events. There is no reason that the bleeding
rate would have been greater than in the previous study6 or with
Fig. 1-C
Observed rate differences for venous thromboembolism (venous thromboembolism rate with the mobile compression device minus venous thrombo-
embolism rate with the pharmacological comparator represented by the circular markers) and the 97.5% confidence intervals between the mobile
compression device and the current pharmacological comparators in patients who had a knee arthroplasty.
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any other compression device study29,30. Compliance, which
increases the effectiveness of compression devices31, was not
documented in the registry. If the participants in this study used
the device less than the ten days and twenty hours per day re-
ported in the previous study6, the venous thromboembolism
rates would only improve with greater use. The study was not
powered to establish any conclusions with respect to the use or
nonuse of aspirin in addition to the mobile compression device.
Of the twenty-eight patients who had a venous thromboembolic
event, 46% were on the aspirin protocol. Similarly, the study was
not powered to assess the relationship between anesthesia type
and the occurrence of venous thromboembolism. The anes-
thesia protocols for hip and knee arthroplasty differed from site
to site, and we were able to present frequencies only (see Ap-
pendix). Another potential study weakness is that each institu-
tion reported its duplex ultrasound data and spiral CT data with
no adjudication committee to evaluate these studies. However, if
any of the positive diagnostic studies had been disallowed by an
adjudication committee, a lower rate of deep venous thrombi
and pulmonary emboli would have been observed.
To our knowledge, this is the first large multicenter study
utilizing an external mobile compression device in an inpatient
or outpatient setting for ten days or greater. The results dem-
onstrated noninferior efficacy in the prevention of venous
thromboembolism compared with the most commonly used
pharmacological protocols, except for rivaroxaban in knee ar-
throplasty, which lacked noninferiority by 0.06% at the 1.0%
margin. On the basis of this study, we recommend that sur-
geons consider the use of this mobile compression device with
or without aspirin for prophylaxis as an alternative to phar-
macological prophylaxis in patients treated with arthroplasty of
a lower-extremity joint.
Appendix
A table showing patient demographic data is available
with the online version of this article as a data supplement
at jbjs.org. n
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